While we observed different potencies in vivo for the three modalities in targeting pre-B-ALL tumours, these compatible therapeutic strategies give tremendous scope for accommodating the different pharmacodynamic requirements of various LGR5+ tumour types. Here, LGR5 is linked to acute lymphoblastic leukemia.